Open AccessDopaminergic agonist bromocriptin in treatment of diabetes mellitus type 2
Author(s) -
О. А. Герасименко,
Ekaterina Pigarova,
Larisa Dzeranova
Publication year - 2011
Publication title -
ožirenie i metabolizm
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 0.154
H-Index - 5
eISSN - 2306-5524
pISSN - 2071-8713
DOI - 10.14341/2071-8713-5298
Subject(s) - bromocriptine , endocrinology , medicine , dopaminergic , postprandial , agonist , diabetes mellitus , type 2 diabetes mellitus , dopamine agonist , dopamine , type 2 diabetes , dopamine receptor , hypothalamus , insulin , receptor , hormone , prolactin
Bromocriptine is a sympatholytic agonist of dopamine receptors, which is now proposed for treatment of type 2 diabetes mellitus. In animal studies bromocriptine elevates the decreased levels of dopamine in hypothalamus and blocks excessive sympathetic innervations in central nervous system that results in decrease of postprandial glucose. Bromocriptine decreases hepatic glucose production and increases insulin secretion and muscle insulin sensitivity. This article reviews experimental and clinical data on the use of bromocriptine for treatment of type 2 diabetes mellitus